Skip to main content Accessibility help
×
Home
  • Print publication year: 2016
  • Online publication date: March 2016

Chapter 14 - Postoperative nausea and vomiting management: cost-effectiveness and patient outcome

1.Gan, T, Ing, R, de L Dear, G, et al. How much are patients willing to pay to avoid intraoperative awareness? J Clin Anesth 2003; 15: 108–12.
2.Gan, TJ, Diemunsch, P, Habib, AS, et al. SAMBA Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118: 85113.
3.Bishof, RO, Nash, DB. Cost-effectiveness and cost containment. A physician’s primer. Prim Care 1996; 23: 115–26.
4.Coronini-Cronberg, S, Appleby, J, Thompson, J. Application of patient-reported outcome measures (PROMs) data to estimate cost-effectiveness of hernia surgery in England. J R Soc Med 2013; 106: 278–87.
5.Frighetto, L, Loewen, PS, Dolman, J, et al. Cost-effectiveness of prophylactic dolasetron or droperidol vs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery. Can J Anaesth 1999; 46: 536–43.
6.Gillespie, EL, White, CM, Kluger, J, et al. A hospital perspective on the cost-effectiveness of beta-blockade for prophylaxis of atrial fibrillation after cardiothoracic surgery. Clin Ther 2005; 27: 1963–9.
7.Gomes, M, Soares, MO, Dumville, JC, et al. Cost-effectiveness analysis of general anaesthesia versus local anaesthesia for carotid surgery (GALA Trial). Br J Surg 2010; 97: 1218–25.
8.Johnstone, R, Martinec, C. Anesthesia studies should include costs. Anesthesiology 1993; 79: 195–7.
9.Lake, AP, Hugo, S, Coetzee, G, et al. Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery. J Clin Anesth 1995; 7: 551–3.
10.McCabe, C, Claxton, K, Culyer, AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008; 26: 733–44.
11.Parra-Sanchez, I, Abdallah, R, You, J, et al. A time–motion economic analysis of postoperative nausea and vomiting in ambulatory surgery. Can J Anaesth 2012; 59: 366–75.
12.Rennie, L, Porteous, T, Ryan, M. Preferences for managing symptoms of differing severity: a discrete choice experiment. Value Health 2012; 15: 1069–76.
13.Watcha, M. The cost-effective management of postoperative nausea and vomiting (editorial). Anesthesiology 2000; 92: 931–3.
14.Watcha, MF, Smith, I. Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery. J Clin Anesth 1994; 6: 370–7.
15.Chang, P, Okamoto, M, Chen, J, et al. Cost-effectiveness analysis of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting. J Manag Care Pharm 2005; 11: 317–21.
16.Kranke, P, Eberhart, LH. Possibilities and limitations in the pharmacological management of postoperative nausea and vomiting. Eur J Anaesthesiol 2011; 28: 758–65.
17.Kapur, PA. The big “little problem”. Anesth Analg 1991; 73(3):243–5.
18.Gagnon, JP, Osterhaus, JT. Proposed drug–drug cost effectiveness methodology. Ann Pharmacother 2006; 40: 524–8.
19.Drummond, MF, Jefferson, TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275–83.
20.Siegel, JE, Weinstein, MC, Russell, LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1339–41.
21.Weinstein, MC, Siegel, JE, Gold, MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1253–8.
22.Barshes, NR, Chambers, JD, Cantor, SB, et al. A primer on cost-effectiveness analyses for vascular surgeons. J Vasc Surg 2012; 55: 1794–800.
23.Elliot, RA. The economics of anaesthesia. Eur J Anaesthesiol 2001; 18: 205–7.
24.Carroll, NV, Miederhoff, PA, Cox, FM, et al. Costs incurred by outpatient surgical centers in managing postoperative nausea and vomiting. J Clin Anesth 1994; 6: 364–9.
25.Moschetti, K, Favre, D, Pinget, C, et al. Comparative cost-effectiveness analyses of cardiovascular magnetic resonance and coronary angiography combined with fractional flow reserve for the diagnosis of coronary artery disease. J Cardiovasc Magn Reson 2014; 16: 13.
26.Berenguer, F, Bean, RJ, Bozec, L, et al. Coherent x-ray imaging of collagen fibril distributions within intact tendons. Biophys J 2014; 106: 459–66.
27.Diez, L. Assessing the willingness of parents to pay for reducing postoperative emesis in children. Pharmacoeconomics 1998; 13: 589–95.
28.Weinstein, MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008; 46: 343–5.
29.Franken, MG, van Gils, CW, Gaultney, JG, et al. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands. Eur J Cancer 2013; 49: 816.
30.Selby, JV, Beal, AC, Frank, L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA 2012; 307: 1583–4.
31.Black, N, Varaganum, M, Hutchings, A. Relationship between patient reported experience (PREMs) and patient reported outcomes (PROMs) in elective surgery. BMJ Qual Saf 2014; 23: 534542.
32.Myles, PS, Hunt, JO, Nightingale, CE, et al. Development and psychometric testing of a quality of recovery score after general anesthesia and surgery in adults. Anesth Analg 1999; 88: 8390.
33.Basch, E. New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med 2014; 65: 307–17.
34.McDowell, A, Fothergill, JA, Khan, A, et al. A cyclodextrin formulation to improve use of the anesthetic tribromoethanol (Avertin). J Pharm Bioallied Sci 2014; 6: 1621.
35.Madhusudhan, S, Hussain, A, Sahni, JN. Value of anti-VEGF treatment in choroidal neovascularization associated with autosomal recessive bestrophinopathy. Digit J Ophthalmol 2013; 19: 5963.
36.Hajeer, AH, Al Balwi, MA, Aytul Uyar, F, et al. HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in Saudis using next generation sequencing technique. Tissue Antigens 2013; 82: 252–8.
37.Fritzsche, M, Thorogate, R, Charras, G. Quantitative analysis of ezrin turnover dynamics in the actin cortex. Biophys J 2014; 106: 343–53.
38.Institute of Medicine. Evaluation of biomarkers and surrogate endpoints in chronic disease, 2010. www.iomedu/Reports/2010/Evaluation-of-Biomarkers-and-Surrogate-Endpointsin-Chronic-Diseaseaspx
39.Fisher, DM. Surrogate outcomes: meaningful not! Anesthesiology 1999; 90: 355–6.
40.Ricotta, C, Celesti-Grapow, L, Kuhn, I, et al. Geographical constraints are stronger than invasion patterns for European urban floras. PLoS ONE 2014; 9: e85661.
41.Myles, PS, Wengritzky, R. Simplified postoperative nausea and vomiting impact scale for audit and post-discharge review. Br J Anaesth 2012; 108: 423–9.
42.Hall, DP, Maccormick, IJ, Phythian-Adams, AT, et al. Network analysis reveals distinct clinical syndromes underlying acute mountain sickness. PLoS ONE 2014; 9: e81229.
43.Royse, CF, Newman, S, Chung, F, et al. Development and feasibility of a scale to assess postoperative recovery: the post-operative quality recovery scale. Anesthesiology 2010; 113: 892905.
44.Myles, PS, Weitkamp, B, Jones, K, et al. Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth 2000; 84: 11–5.
45.Stark, PA, Myles, PS, Burke, JA. Development and psychometric evaluation of a postoperative quality of recovery score: the QoR-15. Anesthesiology 2013; 118: 1332–40.
46.Berg, K, Kjellgren, K, Unosson, M, et al. Postoperative recovery and its association with health-related quality of life among day surgery patients. BMC Nurs 2012; 11: 24.
47.Phillips, C, Blakey, G, 3rd, Jaskolka, M. Recovery after orthognathic surgery: short-term health-related quality of life outcomes. J Oral Maxillofac Surg 2008; 66: 2110–5.
48.Gornall, BF, Myles, PS, Smith, CL, et al. Measurement of quality of recovery using the QoR-40: a quantitative systematic review. Br J Anaesth 2013; 111: 161–9.
49.Murphy, GS, Szokol, JW, Greenberg, SB, et al. Preoperative dexamethasone enhances quality of recovery after laparoscopic cholecystectomy: effect on in-hospital and postdischarge recovery outcomes. Anesthesiology 2011; 114: 882–90.
50.Kim, SH, Oh, YJ, Park, BW, et al. Effects of single-dose dexmedetomidine on the quality of recovery after modified radical mastectomy: a randomised controlled trial. Minerva Anestesiol 2013; 79: 1248–58.
51.Carlisle, JB, Stevenson, CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2006: CD004125.
52.Kooij, FO, Klok, T, Hollmann, MW, et al. Decision support increases guideline adherence for prescribing postoperative nausea and vomiting prophylaxis. Anesth Analg 2008; 106: 893–8.
53.Pergolizzi, JV, Pappagallo, M, LeQuang, J, et al. New health care measures: emphasis on better management of postsurgical pain and postoperative nausea and vomiting. Hosp Pract (1995) 2014; 42: 6574.
54.Pierre, S, Corno, G, Benais, H, et al. A risk score-dependent antiemetic approach effectively reduces postoperative nausea and vomiting – a continuous quality improvement initiative. Can J Anaesth 2004; 51: 320–5.
55.Kolanek, B, Svartz, L, Robin, F, et al. Management program decreases postoperative nausea and vomiting in high-risk and in general surgical patients: a quality improvement cycle. Minerva Anestesiol 2014; 80: 337–46.
56.Apfel, CC, Laara, E, Koivuranta, M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91: 693700.
57.Frenzel, JC, Kee, SS, Ensor, JE, et al. Ongoing provision of individual clinician performance data improves practice behavior. Anesth Analg 2010; 111: 515–9.
58.Hill, R, Lubarsky, D, Phillips-Bute, B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol or placebo. Anesthesiology 2000; 92: 958–67.
59.Hill, RP, Lubarsky, DA, Phillips-Bute, B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology 2000; 92: 958–67.
60.Tramer, MR, Phillips, C, Reynolds, DJ, et al. Cost-effectiveness of ondansetron for postoperative nausea and vomiting. Anaesthesia 1999; 54: 226–34.
61.Paech, MJ, Rucklidge, MW, Banks, SL, et al. The efficacy and cost-effectiveness of prophylactic 5-hydroxytryptamine3 receptor antagonists: tropisetron, ondansetron and dolasetron. Anaesth Intensive Care 2003; 31: 11–7.
62.Pueyo, FJ, Lopez-Olaondo, L, Sanchez-Ledesma, MJ, et al. Cost-effectiveness of three combinations of antiemetics in the prevention of postoperative nausea and vomiting. Br J Anaesth 2003; 91: 589–92.
63.Sennaraj, B, Shende, D, Ilavajady, S, Sadhasivam, S, Jagan, D. Management of post-strabismus nausea and vomiting in children using ondansetron: a value-based comparison of outcomes. Br J Anaesth 2002; 89: 473–8.
64.Olutoye, O, Jantzen, EC, Alexis, R, et al. A comparison of the costs and efficacy of ondansetron and dolasetron in the prophylaxis of postoperative vomiting in pediatric patients undergoing ambulatory surgery. Anesth Analg 2003; 97: 390–6.